News from ucb, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 08, 2014, 11:00 ET

UCB and Emory Present New Assessment of Epilepsy Prevalence and Incidence in the U.S. at 2014 American Epilepsy Society Annual Meeting

 The Department of Neurology at Emory University School of Medicine and UCB, a global biopharmaceutical company with a focus on epilepsy...

Dec 08, 2014, 01:00 ET

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy

 Today UCB announced the primary efficacy and safety data from the latest Phase 3 study evaluating brivaracetam (fixed doses of 100 and 200...

Dec 04, 2014, 08:00 ET

UCB, Georgia Institute of Technology Partner to Harness the Power of Predictive Analytics in Epilepsy Care

UCB, a global biopharmaceutical company with North America Operations headquarters in Atlanta, today announced a collaboration with the Georgia...

Dec 03, 2014, 01:00 ET

UCB reinforces its leadership in epilepsy at the 2014 Annual Meeting of the American Epilepsy Society (AES)

UCB, a global biopharmaceutical company with a focus on epilepsy treatment and research, announced today that there will be 24 UCB-sponsored...

Nov 14, 2014, 01:00 ET

UCB shows strong scientific presence at leading rheumatology meeting

UCB, a global biopharmaceutical company, is sponsoring 27 data presentations at the American College of Rheumatology/Association of...

Oct 22, 2014, 12:00 ET

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at American College of Gastroenterology 2014 Annual Scientific Meeting

 UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring several data presentations on...

Sep 01, 2014, 01:00 ET

New indication for VIMPAT® (lacosamide): UCB's anti-epileptic drug approved by FDA as monotherapy in the treatment of patients with partial-onset seizures

0700 (CEST) – regulated information -- UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a...

Jul 23, 2014, 08:00 ET

Major advance in UCB pipeline: positive topline Phase 3 results for brivaracetam in epilepsy patients with partial-onset seizures

regulated information -- UCB today announced an important advance in its research and development pipeline with positive topline results from...

Jul 03, 2014, 07:00 ET

UCB and Dermira enter into strategic collaboration in dermatology to broaden patient access to Cimzia® (certolizumab pegol)

 UCB, a global biopharmaceutical leader (Euronext: UCB), and Dermira, Inc., a privately held US-based dermatology company, announced today that...

May 05, 2014, 09:07 ET

UCB Announces Data from First Seven Year Evaluation of Cimzia® (certolizumab pegol) in Moderate to Severe Crohn's Disease Patients

 UCB announced today results from the PRECiSE 3 7-year open label extension clinical trial of Cimzia® (certolizumab pegol), the longest...

Apr 30, 2014, 07:30 ET

First Results Presented from Study of U.S. Veterans Using a Health Data Sharing Network Show Measurable Improvements in Epilepsy Self-Management

 Today, the U.S. Department of Veterans Affairs' Epilepsy Centers of Excellence (ECoE), biopharmaceutical company UCB, and health data sharing...

Nov 20, 2013, 07:00 ET

New data from UCB's epilepsy portfolio to be highlighted at the 67th Annual Meeting of the American Epilepsy Society

  UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, will be sponsoring 15 data presentations at...

Nov 04, 2013, 07:00 ET

UCB files VIMPAT® (lacosamide) in the US as monotherapy treatment in adult epilepsy patients with partial-onset seizures

 UCB announced that the US Food and Drug Administration (FDA) has accepted for filing a supplemental new drug application (sNDA) for...

Oct 25, 2013, 07:00 ET

UCB-sponsored Data on Cimzia® (certolizumab pegol) to be Highlighted at 2013 American College of Rheumatology Annual Scientific Meeting

 UCB, a global biopharmaceutical company focusing on CNS and immunology treatment and research, is sponsoring multiple data presentations on...

Oct 18, 2013, 07:00 ET

Cimzia® (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis

regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia® (certolizumab...

Oct 03, 2013, 11:30 ET

UCB highlights educational support programs for people living with Parkinson's disease at the World Parkinson Congress

 UCB today announced two poster presentations at the 2013 World Parkinson Congress (WPC) highlighting key Parkinson's disease (PD) patient...

Sep 30, 2013, 07:00 ET

Cimzia® (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis

 regulated information – UCB announced today that the U.S. Food and Drug Administration (FDA) has approved Cimzia®...

Aug 29, 2013, 12:41 ET

NEUPRO® (rotigotine) Now Available in Canada to Treat Parkinson's Disease

TORONTO, Aug. 29, 2013 /CNW/ - UCB Canada Inc. announced today that NEUPRO® (rotigotine) is now available in Canada for the treatment of...

Jul 10, 2013, 08:50 ET

UCB's Kremers Urban Pharmaceuticals Inc. receives FDA approval for extended release methylphenidate hydrochloride

- regulated information - UCB announced today that Kremers Urban Pharmaceuticals Inc. (KU), its U.S. subsidiary focused on specialty generics,...

Jun 18, 2013, 09:07 ET
Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy.  (PRNewsFoto/UCB, Inc.)

Professional Golfer Jeff Klauk Tees Off New Pledge Campaign for People Living with Epilepsy

 regulated information — Global biopharmaceutical company UCB, Inc. and professional golfer Jeff Klauk today announced the launch of a...